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The foot-and-mouth disease virus (FMDV) capsid is highly acid labile, but introduction of amino acid replacements, including
an N17D change in VP1, can increase its acid resistance. Using mutant VP1 N17D as a starting point, we isolated a virus with
higher acid resistance carrying an additional replacement, VP2 H145Y, in a residue highly conserved among picornaviruses,
which has been proposed to be responsible for VP0 cleavage. This mutant provides an example of the multifunctionality of
picornavirus capsid residues.
The picornavirus foot-and-mouth disease virus (FMDV) is theetiological agent of a highly contagious disease that affects clo-
ven-hoofed animals, including important livestock species (1, 2).
FMDV virions are arranged in an icosahedral capsid built by 60
copies of each of the four structural proteins (VP1 to VP4) ar-
ranged into 12 pentameric subunits that constitute the interme-
diates for capsid assembly and disassembly (3–5). The FMDV cap-
sid disassembles into pentameric subunits at mildly acidic pH.
This property of the capsid is key for the viral RNA uncoating that
takes advantage of endosomal acidification during virus internal-
ization in host cells (6–9). We previously reported that a single
amino acid substitution at the N terminus of VP1 protein (VP1
N17D) selected in mutant m6 after treatment with pH 6.0 con-
ferred increased resistance to acidic pH to type C FMDV isolate
C-S8c1 (10). Similar findings have been recently described for
type O FMDV (11). Here we report the isolation and character-
ization of a novel mutant from m6 population that displays an
even higher degree of resistance to acidic pH.
About 2  106 PFU of m6 mutant was incubated 30 min in
phosphate-buffered saline (PBS) at pH 5.2, pH was neutralized
with 1 M Tris at pH 7.5, and these samples were used to infect
BHK-21 cells in semisolid agar medium (10). Individual plaques
developed after 24 h of infection were amplified by infection in
liquid medium (48 h). The viral populations recovered were sub-
jected to treatment with pH 5.2 and amplified again (48 h). One of
them, termed sr1, displayed a marked increase in its resistance to
treatment with acidic pH compared to m6 and C-S8c1 (Fig. 1A),
with pH50 values— defined as the pH that causes a loss of 50% of
the infectivity (9)— of 5.4, 6.1, and 6.75 for sr1, m6, and C-S8c1,
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FIG 1 FMDV mutant sr1 displays an increased resistance to acidic pH without major effects on virus growth. (A) Acid sensitivity of C-S8c1, m6, and sr1 viruses.
Equal amounts (PFU) of the different viruses were treated 30 min at room temperature with PBS at different pHs, as described previously (9). The samples were
then neutralized with Tris at 1 M and pH 7.5 and added to BHK-21 monolayers. Infectivity was calculated as the percentage of PFU recovered at each different
pH relative to that obtained at pH 7.5. The intersections between the inactivation curves and dashed line indicate pH50 values; see the text for details. (B) Analysis
of viral plaque size of C-S8c1, m6, and sr1. BHK-21 cells were infected in agar semisolid medium, and plaques were visualized by staining with crystal violet. About
100 viral plaques were analyzed for each virus. Asterisks (*) denote statistically significant differences (analysis of variance [ANOVA] P 0.05). (C) Single-step
growth curve analysis of C-S8c1, m6, and sr1. BHK-21 cells were infected (multiplicity of infection [MOI] of 1 PFU/cell), and the virus titer in the supernatants
was determined by plaque assay at different times postinfection. Data are presented as means standard deviations.
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respectively. Thus, mutant sr1 displayed an increase of more than
1 pH unit in resistance to acidic pH compared to the parental
C-S8c1. Mutant sr1 showed only a slight reduction in plaque size
compared with those of m6 and CS8c1 (Fig. 1B), and no major
differences in their viral growth curves were noticed (Fig. 1C).
Sequencing of the capsid coding region, as described in refer-
ences 9 and 10, revealed that the sr1 population retained the nu-
cleotide substitution A3256G leading to replacement VP1 N17D
present in mutant m6 and had acquired substitution C2329T lead-
ing to replacement VP2 H145Y as the only changes relative to
C-S8c1 (12). Infectious clones encoding the complete genomic
sequence of C-S8c1 virus (13) were engineered to carry substitu-
tion VP2 H145Y either alone or combined with replacement VP1
N17D, and the corresponding viruses were recovered by transfec-
tion of BHK-21 cells with in vitro-synthesized viral transcripts (9,
10). Mutant VP2 H145Y and mutant VP1 N17D  VP2 H145Y
showed a plaque size slightly smaller than those of VP1 N17D and
the wild type (WT) (C-S8c1) (Fig. 2A), and no reversion to the
parental sequence or further substitutions were detected in the
capsid region of any of these viruses upon 6 passages. Relative to
the C-S8c1 virus recovered from the infectious clone (pH50 of
6.75), VP2 H145Y replacement induced an increase in resistance
to acidic pH slightly lower (pH50 of 6.3) than that of VP1 N17D
(pH50 of 6.05, comparable to that of m6) (Fig. 2B). These increases
were lower than that observed for the double mutant VP1
N17D  VP2 H145Y (pH50 of 5.35, comparable to that of sr1),
indicating an additive effect of replacements VP1 N17D and VP2
H145Y on FMDV resistance to acidic pH. VP2 H145 (equivalent
to poliovirus H195) is a highly conserved residue among picorna-
viruses that has been proposed to promote the autocatalytic RNA-
dependent cleavage of the capsid precursor VP0 into VP2 and VP4
(14, 15). In poliovirus, substitution of H195 by threonine, argi-
FIG 2 Amino acid substitution VP2 H145Y increases acid resistance of FMDV. (A) Analysis of plaque size of viruses recovered from infectious clone pMT28
(WT) and its derivatives encoding different amino acid substitutions found in mutant m6 (VP1 N17D) or mutant sr1 (VP1 N17DVP2 H145Y) or VP2 H145Y
alone. BHK-21 cells were infected in agar semisolid medium, and plaques were visualized by staining with crystal violet. About 100 viral plaques were analyzed
for each virus. Asterisks (*) denote statistically significant differences (ANOVA P 0.05). (B) Acid sensitivity of viruses recovered from infectious clone pMT28
and its derivatives shown in panel A. Equal PFU of the different viruses were treated and plated on BHK-21 monolayers as described for Fig. 1. Infectivity was
calculated as the percentage of PFU recovered at each different pH relative to that obtained at pH 7.5. The intersections between the inactivation curves and
dashed line indicate pH50 values; see the text for details. (C) Western blot analysis of purified virions of C-S8c1, m6, and sr1. Virions were purified from tissue
culture supernatants through a 20% sucrose cushion followed by centrifugation in a 7.5% to 30% sucrose density gradient (9). The peak fraction containing the
virions was loaded in 12% SDS-PAGE and analyzed by Western blotting using monoclonal antibody SD6 (anti-VP1), anti-VP2 (4A3), or anti-VP3 (6C2) (25, 26).
The expected migration of VP0 (26) is indicated by an arrow. (D) Location on the structure of the C-S8c1 capsid (5) of amino acid residues found to be substituted
in FMDV mutants with increased resistance to acid inactivation. An inside schematic view of a pentameric subunit in the capsid is shown. VP1 is green, VP2 is
magenta, VP3 is cyan, and VP4 is yellow.
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nine, glycine, or aspartic acid impaired VP0 cleavage and was
lethal (14). Structural analyses suggest that the role of this histi-
dine residue is conserved in both FMDV and poliovirus (15), al-
beit the cleavage of FMDV and that of poliovirus VP0 may differ in
some aspects. Indeed, poliovirus empty capsids display VP0 (16),
whereas FMDV empty capsids exhibit VP2 and VP4 (15). Our
results show that no VP0 was detected in purified virions of mu-
tant sr1 (Fig. 2C), suggesting that replacement of histidine by
tyrosine does not impair its putative role in VP0 cleavage. VP2
H145 is located about 18 Å from VP1 N17D, close to an VP2 F34
residue (Fig. 2D) in which replacement F34L was found accom-
panying substitution VP1 N17D in another acid-resistant mutant
(10). This indicates the importance of this region for acid resis-
tance. VP2 H145 establishes a hydrogen bond with VP2 T33 and is
close to residues 6 to 9 at the N terminus of VP1, a region of the
capsid also involved in acid resistance (10, 17). The protonation at
mildly acidic pH (about 6.5) of two histidines of VP3 located near
the border of the pentameric subunit has been associated with
electrostatic repulsions between neighbor pentamers that induce
capsid disassembly (18, 19). The pKa of 5.25 for VP2 H145 side
chain, calculated with PROPKA (20), is compatible with its pro-
tonation at more acidic pH, which should be abolished by replace-
ment VP2 H145Y. Since H145 is located in an internal region of
the capsid at the intraprotomeric interface, not at the pentameric
interface, replacement VP2 H145Y could also impact the
protomer conformation, affecting pentamers and hence capsid
stability. Indeed, mutations in central regions of intermediates for
capsid assembly can affect assembly of viral capsids (21).
The acid resistance of mutant m6 correlated with a lower sen-
sitivity to heat inactivation relative to C-S8c1 virus (10). Thermal
stability of FMDV virions is important for the immunogenicity of
FMDV vaccines based on chemically inactivated virus whose effi-
cacy is reduced when the cold chain (4°C) is broken or upon
long-term storage (22, 23). Virions of C-S8c1, m6, and sr1 were
purified by ultracentrifugation in sucrose gradients (9, 10) and
stored at 4°C. After 15 weeks of storage, C-S8c1 virions had com-
pletely dissociated into pentameric subunits whereas m6 and sr1
preparations conserved a high proportion (about 80%) of virions
FIG 3 Mutant sr1 virions display increased stability at 4°C and acidic pH. (A) Analysis of the stability of virions of C-S8c1, m6, and sr1 at 4°C. Virions from
C-S8c1, m6, and sr1 were purified from tissue culture supernatants as described for Fig. 2 and then dialyzed against PBS at pH 7.4. Purified virions were stored
at 4°C for 15 weeks. The proportion of virions and pentamers (sedimentation coefficients of 140S and 12S, respectively) in each sample was determined by
ultracentrifugation of the samples in a 7.5% to 45% sucrose density gradient (9) and analysis of fractions collected from the top of the gradients by dot blot using
monoclonal antibody SD6 (anti-VP1) and chemiluminescence detection. Quantification of the integrated density in each dot corresponding to a fraction of the
gradient is shown in the graphs. (B) Analysis of virion integrity after acid treatment. Purified virions of sr1 and m6 mutants prepared and stored as described for
panel A were incubated with PBS at pH 7.2 (control) or 6.2 (acid treated) for 30 min at room temperature, and the proportion of virions and pentamers in each
sample was determined by ultracentrifugation of the samples in a 7.5% to 45% sucrose density gradient and analysis by dot blotting using antibody SD6 and
chemiluminescence detection. Quantification of the integrated density in each dot corresponding to a fraction of the gradient is shown in the graphs.
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(Fig. 3A), confirming an increase in thermal stability at 4°C that
could be advantageous for vaccine design. When the acidic sensi-
tivity of these preparations was tested (Fig. 3B), an increased re-
sistance to acid-induced dissociation of sr1 relative to m6 was
noticed.
To analyze the effect of VP1 N17D and VP2 H145Y on virus
antigenicity, we used an enzyme immunodot assay (24) that in-
cluded a representative panel of virus-neutralizing monoclonal
antibodies directed against different epitopes located at the anti-
genic sites identified in C-S8c1—site A (SD6), site C (7JA1), and
site D (1G5, 2E5, and 5C4) (5). Relative to the parental virus,
viruses carrying amino acid replacement VP1 N17D or VP2
H145Y or both replacements were recognized by all the antibodies
in similar manners (data not shown). Further work, including the
analysis of the immunogenicity of these mutants in natural hosts,
is required to address the potential of these mutations to increase
the stability of FMDV vaccines.
In summary, replacement VP2 H145Y confers resistance to
acidic pH, leading to higher levels of resistance when combined
with substitution VP1 N17D. Replacement H145Y did not result
in major impairment of processing of either VP0, as no VP0 was
detected in virions carrying this mutation, or virus growth. Our
data provide unexpected evidence of the multifunctionality of this
residue in the FMDV capsid.
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